WKWalid Hamdy Kilany

Walid Hamdy Kilany

*This is an algorithmically generated author record based on publicly available information.

Walid Hamdy Kilany has a total of 131 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Multivalent Inactivated Vaccine Protects Chickens from Distinct Clades of Highly Pathogenic Avian Influenza Subtypes H5N1 and H5N8

    by Walid H. Kilany, Marwa Safwat, Mohamed A. Zain El-Abideen, Islam Hisham, Yasmine Moussa, Ahmed Ali, Magdy F. Elkady

    Background/Objective: Highly pathogenic avian influenza (HPAI) H5 subtype remains a significant menace to both the poultry industry and human public health. Biosecurity and mass vaccination of susceptible commercial poultry flocks are crucial to reduce the devastating economic loss and hinder the evolution of the virus. Methods: In this study, we developed a multivalent avian influenza virus (AIV) vaccine, including strains representing the HPAI 2.2.1.1., 2.2.1.2., and 2.3.4.4b clades circulating in Egypt and the Middle East. Specific pathogen-free (SPF) two-week-old chickens were vaccinated with a single vaccine shot and observed for four weeks post-vaccination before being challenged. The challenge experiment involved using one strain of HPAI H5N1 subtype clade 2.2.1.2 and two strains of HPAI H5N8 subtype clade 2.3.4.4b derived from chickens and ducks. To assess the vaccine’s potency and efficacy, the pre-challenge humoral immune response and post-challenge survival and virus shedding were evaluated. Results: All the vaccinated birds exhibited 100% seroconversion 2 weeks post-vaccination (2 WPV). In addition, protective antibody titers against each diagnostic antigen, i.e., 7.8 ± 1.8 (H5N1, clade 2.2.1.2), 10.0 ± 0.0 (H5N1, clade 2.2.1.1), and 7.5 ± 0.9 (H5N8, clade 2.3.4.4b) were detected 3 WPV. The vaccination achieved complete protection (100%) against all challenge viruses with no disease symptoms. The vaccinated birds exhibited a statistically significant reduction in oropharyngeal virus shedding 2 days post-challenge (DPC). Conclusions: This study illustrated that a single application of a multivalent genetic-matching whole AIV vaccine under laboratory conditions elicits adequate protection against the HPAI challenge, representing 2.2.1.2 and 2.3.4.4b clades. The developed vaccine has the potential to be a vaccine of choice against a broad range of HPAI in commercial flocks raised under field conditions in endemic areas.


  • Evaluation of different heterologous-homologous vaccine regimens against challenge with GI-23 lineage infectious bronchitis virus

    by Mohamed H. Houta, Kareem E. Hassan, Walid H. Kilany, Salama A.S. Shany, Azza A. El-Sawah, Magdy F. ElKady, Ahmed S. Abdel-Moneim, Ahmed Ali


  • Open Access

    Genotype VII.1.1-Based Newcastle Disease Virus Vaccines Afford Better Protection against Field Isolates in Commercial Broiler Chickens

    by Abdelmonem A. A. Dewidar, Walid H. Kilany, Azza A. El-Sawah, Salama A. S. Shany, Al-Hussien M. Dahshan, Islam Hisham, Magdy F. Elkady, Ahmed Ali

    This study evaluated the efficacy of live and inactivated conventional GII LaSota and recombinant GVII Newcastle disease vaccines in commercial broilers. The experimental groups (G2–G7) were vaccinated on day 7 and day 21 of age with live vaccines from the same vaccine type “GII LaSota, GVII vaccine (A), GVII vaccine (B)” via eye drop; however, G3, G5, and G7 received a single dose from inactivated counterpart vaccines subcutaneously on day 7 of age. Vaccine efficacy was evaluated based on elicited humoral immunity, clinical protection, and reduction in virus shedding after challenge with virulent GVII 1.1. strain. Results demonstrated that live and inactivated recombinant GVII vaccine based on VG/GA strain backbone elicited superior protection parameters (100% protection). Although the conventional GII LaSota live and inactivated vaccination regime protected 93.3% of vaccinated birds, the virus shedding continued until 10 DPC. The post-vaccination serological monitoring was consistent with protection results. The study concludes that conventional GII ND vaccines alone are probably insufficient due to the current epidemiology of the GVII 1.1 NDV strains. Our findings further support that protection induced by recombinant GVII 1.1. ND vaccines are superior. Interestingly, the efficacy of recombinant ND vaccines seemed to be influenced by the backbone virus since the VG/GA backbone-based vaccine provided better protection and reduced virus shedding.


  • Open Access

    Combined H5ND inactivated vaccine protects chickens against challenge by different clades of highly pathogenic avian influenza viruses subtype H5 and virulent Newcastle disease virus

    by Ahmed Ali, Marwa Safwat, Walid H. Kilany, Abdou Nagy, Awad A. Shehata, Mohamed A. Zain El-Abideen, Al-Hussien M. Dahshan, Abdel-Satar A. Arafa

    Aim: The aim of the current study was to evaluate the efficacy of a trivalent-inactivated oil-emulsion vaccine against challenge by different clades highly pathogenic avian influenza (HPAI) viruses including HPAI-H5N8 and the virulent genotype VII Newcastle disease virus (NDV) (vNDV). Materials and Methods: The vaccine studied herein is composed of reassortant AI viruses rgA/Chicken/Egypt/ ME1010/2016 (clade 2.2.1.1), H5N1 rgA/Chicken/Egypt/RG-173CAL/2017 (clade 2.2.1.2), and "NDV" (LaSota NDV/ CK/Egypt/11478AF/11); all used at a concentration of 108 EID50/bird and mixed with Montanide-ISA70 oil adjuvant. Two-week-old specific pathogen free (SPF) chickens were immunized subcutaneously with 0.5 ml of the vaccine, and hemagglutination inhibition (HI) antibody titers were monitored weekly. The intranasal challenge was conducted 4 weeks post-vaccination (PV) using 106 EID50/0.1 ml of the different virulent HPAI-H5N1 viruses representing clades 2.2.1, 2.2.1.1, 2.2.1.2, 2.3.4.4b-H5N8, and the vNDV. Results: The vaccine induced HI antibody titers of >6log2 against both H5N1 and NDV viruses at 2 weeks PV. Clinical protection against all HPAI H5N1 viruses and vNDV was 100%, except for HPAI H5N1 clade-2.2.1 and HPAI H5N8 clade- 2.3.4.4b viruses that showed 93.3% protection. Challenged SPF chickens showed significant decreases in the virus shedding titers up to <3log10 compared to challenge control chickens. No virus shedding was detected 6 "days post-challenge" in all vaccinated challenged groups. Conclusion: Our results indicate that the trivalent H5ND vaccine provides significant clinical protection against different clades of the HPAI viruses including the newly emerging H5N8 HPAI virus. Availability of such potent multivalent oil-emulsion vaccine offers an effective tool against HPAI control in endemic countries and promises simpler vaccination programs.


  • Open Access

    Field Efficacy of an Attenuated Infectious Bronchitis Variant 2 Virus Vaccine in Commercial Broiler Chickens

    by Mohamed A. Elhady, Ahmed Ali, Walid H. Kilany, Wael K. Elfeil, Hytham Ibrahim, Ahmed Nabil, Ahmed Samir, Magdy El Sayed

    Egyptian poultry suffer from frequent respiratory disease outbreaks associated with Infectious Bronchitis Virus (IBV) variant 2 strains (Egy/VarII). Different vaccination programs using imported vaccines have failed to protect the flocks from field challenge. Recent studies confirmed a successful protection using homologous strains as live attenuated vaccines. In this study, a newly developed live attenuated IB-VAR2 vaccine representing the GI-23 Middle East IBV lineage was evaluated in day-old commercial broilers in an IBV-endemic area. A commercial broiler flock was vaccinated with the IB-VAR2 vaccine at day-old age followed by IB-H120 at day 16. The vaccinated flock was monitored on a weekly basis till the slaughter age. The health status and growth performance were monitored, and selected viral pathogen real-time RT-PCR (rRT-PCR) detection was conducted on a weekly basis. Finally, the flock was compared to a nearby farm with only the classical IB-H120 vaccination program. Results showed that the IB-VAR2 vaccine was tolerable in day-old broiler chicks. The IBV virus rRT-PCR detection was limited to the trachea as compared to its nephropathogenic parent virus. Respiratory disease problems and high mortalities were reported in the IB-H120-only vaccinated flock. An exposure to a wild-type Egy/VarII strain was confirmed in both flocks as indicated by partial IBV S1 gene sequence. Even though the IB-VAR2-vaccinated flock performance was better than the flock that received only IB-H120, the IBV ELISA (enzyme-linked immunosorbent assay) and log2 Haemagglutination inhibition (HI) antibody mean titers remained high (3128 ± 2713 and ≥9 log2, respectively) until the 28th day of age. The current study demonstrates the safety and effectiveness of IB-VAR2 as a live attenuated vaccine in day-old commercial broilers. Also, the combination of IB-VAR2 and classical IBV vaccines confers a broader protective immune response against IBV in endemic areas.


  • Open Access

    Protective Efficacy of Recombinant Turkey Herpes Virus (rHVT-H5) and Inactivated H5N1 Vaccines in Commercial Mulard Ducks against the Highly Pathogenic Avian Influenza (HPAI) H5N1 Clade 2.2.1 Virus

    by Walid H Kilany, Marwa Safwat, Samy M Mohammed, Abdullah Salim, Folorunso Oludayo Fasina, Olubunmi G Fasanmi, Azhar G Shalaby, Gwenaelle Dauphin, Mohammed K Hassan, Juan Lubroth, et al.

    In Egypt, ducks kept for commercial purposes constitute the second highest poultry population, at 150 million ducks/year. Hence, ducks play an important role in the introduction and transmission of avian influenza (AI) in the Egyptian poultry population. Attempts to control outbreaks include the use of vaccines, which have varying levels of efficacy and failure. To date, the effects of vaccine efficacy has rarely been determined in ducks. In this study, we evaluated the protective efficacy of a live recombinant vector vaccine based on a turkey Herpes Virus (HVT) expressing the H5 gene from a clade 2.2 H5N1 HPAIV strain (A/Swan/Hungary/499/2006) (rHVT-H5) and a bivalent inactivated H5N1 vaccine prepared from clade 2.2.1 and 2.2.1.1 H5N1 seeds in Mulard ducks. A 0.3ml/dose subcutaneous injection of rHVT-H5 vaccine was administered to one-day-old ducklings (D1) and another 0.5ml/dose subcutaneous injection of the inactivated MEFLUVAC was administered at 7 days (D7). Four separate challenge experiments were conducted at Days 21, 28, 35 and 42, in which all the vaccinated ducks were challenged with 106EID50/duck of H5N1 HPAI virus (A/chicken/Egypt/128s/2012(H5N1) (clade 2.2.1) via intranasal inoculation. Maternal-derived antibody regression and post-vaccination antibody immune responses were monitored weekly. Ducks vaccinated at 21, 28, 35 and 42 days with the rHVT-H5 and MEFLUVAC vaccines were protected against mortality (80%, 80%, 90% and 90%) and (50%, 70%, 80% and 90%) respectively, against challenges with the H5N1 HPAI virus. The amount of viral shedding and shedding rates were lower in the rHVT-H5 vaccine groups than in the MEFLUVAC groups only in the first two challenge experiments. However, the non-vaccinated groups shed significantly more of the virus than the vaccinated groups. Both rHVT-H5 and MEFLUVAC provide early protection, and rHVT-H5 vaccine in particular provides protection against HPAI challenge.


  • Introduction and enzootic of A/H5N1 in Egypt: Virus evolution, pathogenicity and vaccine efficacy ten years on

    by E.M. Abdelwhab, M.K. Hassan, A.S. Abdel-Moneim, M.M. Naguib, A. Mostafa, I.T.M. Hussein, A. Arafa, A.M. Erfan, W.H. Kilany, M.G. Agour, et al.


  • Added Value of Avian Influenza (H5) Day-Old Chick Vaccination for Disease Control in Egypt

    by Marisa Peyre, Marc Choisy, Heba Sobhy, Walid H Kilany, Marie Gély, Astrid Tripodi, Gwenaëlle Dauphin, Mona Saad, François Roger, Juan Lubroth, et al.

    SUMMARY. The immunity profile against H5N1 highly pathogenic avian influenza (HPAI) in the commercial poultry value chain network in Egypt was modeled with the use of different vaccination scenarios. The model estimated the vaccination coverage, the protective seroconversion level, and the duration of immunity for each node of the network and vaccination scenario. Partial budget analysis was used to compare the benefit-cost of the different vaccination scenarios. The model predicted that targeting day-old chick avian influenza (AI) vaccination in industrial and large hatcheries would increase immunity levels in the overall poultry population in Egypt and especially in small commercial poultry farms (from 60%). This strategy was shown to be more efficient than the current strategy of using inactivated vaccines. Improving HPAI control in the commercial poultry sector in Egypt would have a positive impact to improve disease control. RESUMEN. Nota de investigación- Utilidad de la vacunación contra la influenza aviar (H5) en pollos de un día de edad para el control de la enfermedad en Egipto. El perfil de la inmunidad contra el virus de la influenza aviar altamente patógena H5N1 en la red de la cadena de la avicultura comercial en Egipto fue modelada con el uso de diferentes escenarios de vacunación. El modelo estima la cobertura de vacunación, el nivel de seroconversión de protección, y la duración de la inmunidad para cada nodo de la cadena y escenario de vacunación. Se utilizó el análisis de presupuesto parcial para comparar el costo-beneficio de los diferentes escenarios de vacunación. El modelo predijo que la vacunación contra la influenza aviar en pollos de un día de edad en incubadoras comerciales aumentaría los niveles de inmunidad en la población avícola total en Egipto y sobre todo en las pequeñas granjas avícolas comerciales (de 60%). Esta estrategia ha demostrado ser más eficiente que la estrategia actual de utiliza...


  • Experimental and Field Results Regarding Immunity Induced by a Recombinant Turkey Herpesvirus H5 Vector Vaccine Against H5N1 and Other H5 Highly Pathogenic Avian Influenza Virus Challenges

    by Yannick Gardin, Vilmos Palya, Kristi Moore Dorsey, John El-Attrache, Francesco Bonfante, Sjaak de Wit, Darrell Kapczynski, Walid Hamdy Kilany, Fabienne Rauw, Mieke Steensels, et al.

    SUMMARY: Vaccination against H5N1 highly pathogenic avian influenza (AI) virus (HPAIV) is one of the possible complementary means available for affected countries to control AI when the disease has become, or with a high risk of becoming, endemic. Efficacy of the vaccination against AI relies essentially, but not exclusively, on the capacity of the vaccine to induce immunity against the targeted virus (which is prone to undergo antigenic variations), as well as its capacity to overcome interference with maternal immunity transmitted by immunized breeding hens to their progeny. This property of the vaccine is a prerequisite for its administration at the hatchery, which assures higher and more reliable vaccine coverage of the populations than vaccination at the farm. A recombinant vector vaccine (Vectormune® AI), based on turkey herpesvirus expressing the hemagglutinin gene of an H5N1 HPAIV as an insert, has been used in several experiments conducted in different research laboratories, as well as in control... RESUMEN. Nota de investigación- Resultados experimentales y de campo sobre la inmunidad inducida por una vacuna recombinante con el virus HVT como vector con el gene H5 contra el desafío con virus de la influenza altamente patógeno subtipo H5N1 y con otros virus H5. La vacunación contra el virus H5N1 de la influenza aviar altamente patógena es uno de los medios complementarios posibles disponibles para controlar a la influenza aviar en los países afectados donde la enfermedad se ha convertido, o con alto riesgo de convertirse endémica. La eficacia de la vacunación contra la influenza aviar se basa esencialmente, pero no exclusivamente, en la capacidad de la vacuna para inducir inmunidad contra el virus al que está dirigida (el cual es posible que pueda sufrir variaciones antigénicas), así como su capacidad para superar la interferencia con la inmunidad materna transmitida por las gallinas reproductoras inmunizadas a su progenie. Esta propiedad de la vacuna es un requisito previo para su administración en ...


  • Comparative Effectiveness of Two Oil Adjuvant–Inactivated Avian Influenza H9N2 Vaccines

    by Walid H. Kilany, Abdel-Hamid I. Bazid, Ahmed Ali, Ayman H. El-Deeb, Mohamed A. Zain El-Abideen, Magdy El Sayed, Magdy F. El-Kady

    SUMMARY. Low pathogenic avian influenza H9N2 virus infection has been an important risk to the Egyptian poultry industry since 2011. Economic losses have occurred from early infection and co-infection with other pathogens. Therefore, H9N2 vaccination of broiler chicks as young as 7 days old was recommended. The current inactivated H9N2 vaccines (0.5 ml/bird) administered at a reduced dose (0.25 ml/bird) do not guarantee the delivery of an effective dose for broilers. In this study, the efficacy of the reduced-dose volume (0.3 ml/bird), compared with the regular vaccine dose (0.5 ml/bird) of inactivated H9N2 vaccines using two different commercially available adjuvants, was investigated. The vaccines were prepared from the local H9N2 virus (Ck/EG/114940v/NLQP/11) using the same antigen content: 300 hemagglutinating units. Postvaccination (PV) immune response was monitored using the hemagglutination inhibition test. At 4 wk PV, both vaccinated groups were challenged using the homologous H9N2 strain at a 50%... RESUMEN. Eficacia comparativa de dos vacunas contra la influenza aviar H9N2 inactivadas y emulsionadas en aceite. La infección por el virus de la influenza aviar de baja patogenicidad H9N2 ha sido un riesgo importante para la industria avícola egipcia desde el año 2011. Las pérdidas económicas se han producido por esta infección y por la coinfección con otros patógenos. Por lo tanto, se recomienda la vacunación contra este virus H9N2 en pollos de engorde tan temprano como a los siete días de edad. Las vacunas inactivadas actuales H9N2 (0.5 ml/ave) administradas con una dosis reducida (0.25 ml/ave) no garantizan la aplicación de una dosis eficaz para pollos de engorde. En este estudio se investigó la eficacia del volumen reducido de la dosis (0.3 ml/ave), en comparación con la dosis de vacuna regular (0.5 ml/ave) de las vacunas inactivadas H9N2 utilizando dos adyuvantes diferentes disponibles en el mercado. Las vacunas se prepararon a partir del virus H9N2 local (Pollo/EG/114940v/NLQP/11), utilizando el mi...